SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial.
Saved in:
| Title: | SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial. |
|---|---|
| Authors: | Mena Lora AJ; Division of Infectious Diseases, University of Illinois at Chicago, 808 S Wood St, RM 888, Chicago, IL 60612, USA., Enders K; University of North Carolina, Chapel Hill, NC, USA., Wu H; University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Parra-Rodriguez L; Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Palma C; University of Rochester, Rochester, NY, USA., Saliba K; National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Laverdurre S; Leidos Biomedical Research, Bethesda, MD, USA., Smith PB; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Anstrom KJ; University of North Carolina, Chapel Hill, NC, USA., Bozzette SA; National Center for Advancing Translational Sciences, Bethesda, MD, USA., Powderly WG; Washington University School of Medicine in St. Louis, St. Louis, MO, USA. |
| Source: | Therapeutic advances in infectious disease [Ther Adv Infect Dis] 2025 Apr 22; Vol. 12, pp. 20499361251333617. Date of Electronic Publication: 2025 Apr 22 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 101606715 Publication Model: eCollection Cited Medium: Print ISSN: 2049-9361 (Print) Linking ISSN: 20499361 NLM ISO Abbreviation: Ther Adv Infect Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
